和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HCM 和黄医药

未开盘 07-19 16:00:00 EDT

18.94

-0.25

-1.30%

盘后18.94

+0.000.00%

16:00 EDT

最高19.14	最低18.84	成交量4.20万
今开19.07	昨收19.19	日振幅1.55%
总市值32.34亿	流通市值18.99亿	总股本1.71亿
成交额79.61万	换手率0.04%	流通股本1.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"HCM","market":"US","secType":"STK","nameCN":"和黄医药","latestPrice":18.94,"timestamp":1721419200000,"preClose":19.19,"halted":0,"volume":42011,"hourTrading":{"tag":"盘后","latestPrice":18.94,"preClose":18.94,"latestTime":"16:00 EDT","volume":801,"amount":15170.94,"timestamp":1721419211471},"delay":0,"floatShares":100268269,"shares":170749407,"eps":0.59306,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.25,"latestTime":"07-19 16:00:00 EDT","open":19.07,"high":19.14,"low":18.8425,"amount":796139.244063,"amplitude":0.015503,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.59306,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1721635200000},"adr":1,"listingDate":1458187200000,"adjPreClose":19.19,"adrRate":5,"preHourTrading":{"tag":"盘前","latestPrice":19,"preClose":19.19,"latestTime":"09:29 EDT","volume":100,"amount":1900,"timestamp":1721395769057},"postHourTrading":{"tag":"盘后","latestPrice":18.94,"preClose":18.94,"latestTime":"16:00 EDT","volume":801,"amount":15170.94,"timestamp":1721419211471},"volumeRatio":0.14036962338526257,"impliedVol":0.0517,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/HCM","defaultTab":"news","newsList":[{"id":"2453789532","title":"港股异动 | 和黄医药(00013)再涨超5% 公司近期介绍创新药物进展 机构称研发进展迅速","url":"https://stock-news.laohu8.com/highlight/detail?id=2453789532","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453789532?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:42","pubTimestamp":1721616141,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药(00013)再涨超5%，截至发稿，涨5.41%，报31.2港元，成交额4428.23万港元。消息面上，7月9日，和黄医药举办2024年研发日交流活动，公司管理层在会议中重点分享了候选创新管线的临床数据与市场价值，包括索乐匹尼布在自身免疫性疾病的临床数据及优势分析、索凡替尼在胰腺癌的治疗潜力、HMPL-306用于治疗急性髓系白血病的早期数据分析及III期临床设计。东北证券指出，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。另外，公司管线储备丰富，产品市场空间广阔，不断实现海外放量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00013","BK1161","159992","BK4585","BK1191","BK1574","BK1587","HCM","HSCEI","BK4007","HSTECH","BK4588","06978","YANG","BK4531","BK1588"],"gpt_icon":1},{"id":"2453789273","title":"和黄医药(00013)上涨5.07%，报31.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453789273","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453789273?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:35","pubTimestamp":1721615716,"startTime":"0","endTime":"0","summary":"7月22日，和黄医药(00013)盘中上涨5.07%，截至10:35，报31.1元/股，成交3959.27万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2023年年报，和黄医药营业总收入59.35亿元、净利润7.14亿元。7月31日，和黄医药将披露2024财年中报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/22103541702057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HCM","00013","BK4588","BK1588","BK4531","BK4585","BK1191","BK4007","BK1587"],"gpt_icon":0},{"id":"2451981316","title":"南向资金7月15日净买入和黄医药126.05万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2451981316","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451981316?lang=zh_cn&edition=full","pubTime":"2024-07-16 09:31","pubTimestamp":1721093488,"startTime":"0","endTime":"0","summary":"7月15日, 南向资金增持和黄医药126.05万股，连续5日增持。截止当日收盘，港股通共持有和黄医药15557.54万股，占流通股17.84%。和黄医药近5个交易日上涨11.75%，港股通累计增持378.50万股；近20个交易日上涨4.17%，港股通累计增持451.66万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071609383695c43818&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071609383695c43818&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4531","BK4007","00013","HCM"],"gpt_icon":0},{"id":"2451675425","title":"Trinet Group, Inc.盘中异动 快速上涨5.13%报106.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451675425","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451675425?lang=zh_cn&edition=full","pubTime":"2024-07-16 01:22","pubTimestamp":1721064157,"startTime":"0","endTime":"0","summary":"北京时间2024年07月16日01时22分，Trinet Group, Inc.股票出现波动，股价快速上涨5.13%。Trinet Group, Inc.股票所在的人员配备服务行业中，整体涨幅为1.79%。其相关个股中，Trinet Group, Inc.、Insperity, Inc.、K力涨幅较大，Staffing 360 Solutions, Inc.、兼职精灵、Trinet Group, Inc.较为活跃，换手率分别为16.00%、1.27%、0.75%，振幅较大的相关个股有兼职精灵、Professional Diversity Network, Inc.、Staffing 360 Solutions, Inc.，振幅分别为11.83%、10.95%、9.40%。Trinet Group, Inc.公司简介：Trinet Group Inc通过专业雇主组织，为中小型企业提供外包薪资和人力资本管理解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407160122379681cdbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407160122379681cdbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","HCM","LU2517655028.SGD","LU2517655374.HKD","BK4007","PEO","BK4585","BK4531","TNET","LU2517655291.USD","BK4130"],"gpt_icon":0},{"id":"2450532775","title":"美股异动 | 东北证券维持“买入”评级 和黄医药(HCM.US)涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450532775","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450532775?lang=zh_cn&edition=full","pubTime":"2024-07-12 22:56","pubTimestamp":1720796173,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，和黄医药(HCM.US)股价走高，截至发稿，该股涨超8%，报19.245美元，港股今日收涨逾7%。东北证券研报指，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。另外，公司管线储备丰富，产品市场空间广阔，不断实现海外放量。东北证券维持和黄医药“买入”评级。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["HCM","00013","000686"],"gpt_icon":0},{"id":"2450399135","title":"和黄医药(HCM)升近7% 机构指公司产品近期临床数据优异 料将持续催化公司基本面价值提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2450399135","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450399135?lang=zh_cn&edition=full","pubTime":"2024-07-12 22:12","pubTimestamp":1720793523,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和黄医药(HCM)早盘股价震荡走高，截至发稿，涨6.88%，报19.003美元，成交额116.36万美元。交银国际发布研究报告称，维持和黄医药“买入”评级，目标价40港元。索凡替尼联合PD-1一线治疗胰腺癌疗效令人鼓舞，ASCO GI大会上公表的一项IIT数据显示，索凡替尼联合AS疗法和卡瑞利珠单抗治疗1L PDAC的ORR达50%，mPFS/mOS分别为9及13.3个月，明显优于现有疗法。东北证券表示，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"277733","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM","BK4585","BK1191","BK1588","00013","BK1587","BK4007","BK4531","BK4588"],"gpt_icon":0},{"id":"2450330265","title":"和黄医药盘中异动 股价大涨5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450330265","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450330265?lang=zh_cn&edition=full","pubTime":"2024-07-12 21:30","pubTimestamp":1720791025,"startTime":"0","endTime":"0","summary":"北京时间2024年07月12日21时30分，和黄医药股票出现异动，股价快速拉升5.29%。机构评级方面，在所有17家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。和黄医药股票所在的制药行业中，整体涨幅为0.00%。消息层面，截至21时30分，和黄医药股票正面舆情新闻比例11.11%。该信息摘要如下：交银国际发布研究报告称，维持和黄医药“买入”评级，目标价40港元。该行指出，索凡替尼联合PD-1一线治疗胰腺癌疗效令人鼓舞，ASCO。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712213025aef97a1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712213025aef97a1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCM","BK4585","BK4531","BK4007","BK4588"],"gpt_icon":0},{"id":"2450309402","title":"和黄医药(HCM)盘前涨逾4% 东北证券维持公司“买入”评级 指其管线储备丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2450309402","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450309402?lang=zh_cn&edition=full","pubTime":"2024-07-12 17:19","pubTimestamp":1720775981,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和黄医药(HCM)美股盘前走高，暂升4.05%，报18.5美元。今日港股和黄医药(00013)收涨7.21%，报29.75港元，成交额2.12亿港元。东北证券发研指，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。公司管线储备丰富，产品市场空间广阔，不断实现海外放量。该行预计公司24-26年实现收入7.29/8.66/10.00亿美元，每股收益为-0.06/0.05/0.18美元，维持公司“买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/OTg4YTUxMDE3ODY5MDkyNDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTg4YTUxMDE3ODY5MDkyNDI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"277704","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000686","HCM","00013"],"gpt_icon":0},{"id":"2450306647","title":"美股异动 | 券商唱好 和黄医药盘前涨4% H股今日大幅收涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450306647","media":"市场资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450306647?lang=zh_cn&edition=full","pubTime":"2024-07-12 16:56","pubTimestamp":1720774560,"startTime":"0","endTime":"0","summary":"格隆汇7月12日｜港股和黄医药收涨逾7%，带动和黄医药(HCM.US)美股盘前涨4%，报8.5美元。东北证券研报指，公司近期研发进展迅速，多产品同步发力，展现了优异的临床数据和竞争格局，并不断推进产品全球化，预计将持续催化公司基本面价值提升。另外，公司管线储备丰富，产品市场空间广阔，不断实现海外放量。维持公司“买入”评级。\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-07-12/doc-inccwkrv4545109.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-07-12/doc-inccwkrv4545109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1587","BK4588","BK4531","BK4007","BK4585","BK1588","BK1191","HCM","00013"],"gpt_icon":0},{"id":"2450323397","title":"港股异动 | 和黄医药(00013)再涨超9% 公司近期分享最新管线进展 机构称下半年有多项催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2450323397","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450323397?lang=zh_cn&edition=full","pubTime":"2024-07-12 10:45","pubTimestamp":1720752312,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药再涨超9%，截至发稿，涨7.03%，报29.7港元，成交额1.14亿港元。公司2024年下半年催化剂包括呋喹替尼第二季全球销售和基于FRUTIGA研究的2L胃癌国内审批进展；赛沃替尼基于SAVANNAH研究的全球申报；索乐匹尼布国内核准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4007","BK1587","HSCEI","07226","YANG","BK4588","00013","BK1588","HSTECH","BK4585","BK1191","BK4531","HCM"],"gpt_icon":0},{"id":"2450368067","title":"和黄医药盘中异动 股价大涨5.53%报17.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450368067","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450368067?lang=zh_cn&edition=full","pubTime":"2024-07-11 21:30","pubTimestamp":1720704655,"startTime":"0","endTime":"0","summary":"北京时间2024年07月11日21时30分，和黄医药股票出现波动，股价大幅上涨5.53%。截至发稿，该股报17.57美元/股，成交量3220股，换手率0.00%，振幅0.00%。机构评级方面，在所有16家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。和黄医药股票所在的制药行业中，整体涨幅为0.84%。该信息摘要如下：交银国际发布研究报告称，维持和黄医药“买入”评级，目标价40港元。该行指出，索凡替尼联合PD-1一线治疗胰腺癌疗效令人鼓舞，ASCO。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711213055af91dd1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711213055af91dd1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCM","BK4007","BK4585","BK4531","BK4588"],"gpt_icon":0},{"id":"2450051248","title":"港股异动 | 和黄医药(00013)涨超4% 公司下半年包含呋喹替尼第二季全球销售在内等多项催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2450051248","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450051248?lang=zh_cn&edition=full","pubTime":"2024-07-11 11:26","pubTimestamp":1720668388,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药(00013)涨超4%，截至发稿，涨4.26%，报28.15港元，成交额8556.34万港元。交银国际发布研究报告称，维持和黄医药“买入”评级，目标价40港元。报告中称，公司2024年下半年催化剂包括呋喹替尼第二季全球销售和基于FRUTIGA研究的2L胃癌国内审批进展；赛沃替尼基于SAVANNAH研究的全球申报；索乐匹尼布国内核准。该行指出，索凡替尼联合PD-1一线治疗胰腺癌疗效令人鼓舞，ASCO GI大会上公表的一项IIT数据显示，索凡替尼联合AS疗法和卡瑞利珠单抗治疗1L PDAC的ORR达50%，mPFS/mOS分别为9及13.3个月，明显优于现有疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","HSTECH","HCM","00013","BK4007","BK4585","BK4588","HSCEI","BK1191","BK1587","YANG","07226","BK4531"],"gpt_icon":0},{"id":"2450813082","title":"和黄医药(US ADR)下跌2.02%，报16.51美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450813082","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450813082?lang=zh_cn&edition=full","pubTime":"2024-07-10 21:53","pubTimestamp":1720619609,"startTime":"0","endTime":"0","summary":"7月10日，和黄医药(US ADR)(HCM)盘中下跌2.02%，截至21:53，报16.51美元/股，成交62.64万美元。财务数据显示，截至2023年12月31日，和黄医药(US ADR)收入总额8.38亿美元，同比增长96.52%；归母净利润1.01亿美元，同比增长127.93%。大事提醒：7月31日，和黄医药(US ADR)将于(美东)盘前披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/10215341498783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1191","BK1587","00013","BK4007","BK1588","HCM","BK4531","BK4588","BK4585"],"gpt_icon":0},{"id":"2449971819","title":"和黄医药(00013)下跌5.2%，报27.35元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449971819","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449971819?lang=zh_cn&edition=full","pubTime":"2024-07-08 09:35","pubTimestamp":1720402509,"startTime":"0","endTime":"0","summary":"7月8日，和黄医药(00013)盘中下跌5.2%，截至09:35，报27.35元/股，成交400.64万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2023年年报，和黄医药营业总收入59.35亿元、净利润7.14亿元。7月31日，和黄医药将披露2024财年中报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/08093541424048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1588","BK1587","BK4588","BK4585","BK4531","BK4007","00013","BK1191","HCM"],"gpt_icon":0},{"id":"2449718941","title":"和黄医药(00013)股价下跌5.199%，现价港币$27.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2449718941","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449718941?lang=zh_cn&edition=full","pubTime":"2024-07-08 09:35","pubTimestamp":1720402500,"startTime":"0","endTime":"0","summary":"[下跌股]和黄医药(00013) 股价在上午09:35比前收市价下跌5.199%，现股价为港币$27.35。至目前为止，今日最高价为$28.55，而最低价为$27.35。总成交量为13.45万股，总成交金额为港币$376.012万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD240708308/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HCM","BK4007","00013","BK1191","BK4531","BK4585","BK1587","BK4588","BK1588"],"gpt_icon":0},{"id":"2449834293","title":"和黄医药(US ADR)上涨5.14%，报18.42美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449834293","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449834293?lang=zh_cn&edition=full","pubTime":"2024-07-05 21:57","pubTimestamp":1720187865,"startTime":"0","endTime":"0","summary":"7月5日，和黄医药(US ADR)(HCM)盘中上涨5.14%，截至21:57，报18.42美元/股，成交96.97万美元。财务数据显示，截至2023年12月31日，和黄医药(US ADR)收入总额8.38亿美元，同比增长96.52%；归母净利润1.01亿美元，同比增长127.93%。大事提醒：7月31日，和黄医药(US ADR)将于(美东)盘前披露2024财年中报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/05215741410689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1587","BK4007","BK1191","BK4531","BK4585","BK1588","00013","HCM","BK4588"],"gpt_icon":0},{"id":"2449236683","title":"港股异动 | 和黄医药(00013)午后涨超5% 他泽司他新药上市申请获国家药监局受理并予以优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2449236683","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449236683?lang=zh_cn&edition=full","pubTime":"2024-07-05 14:01","pubTimestamp":1720159267,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药午后涨超5%，截至发稿，涨4.59%，报28.5港元，成交额4486.85万港元。消息面上，和黄医药宣布，他泽司他用于治疗复发或难治性滤泡性淋巴瘤成人患者的新药上市申请已获中国国家药品监督管理局受理并予以优先审评。据悉，他泽司他是由益普生旗下公司Epizyme,Inc开发的全球同类首创的EZH2甲基转移酶抑制剂，已获美国食品药品监督管理局加速批准用于治疗特定的复发/难治性滤泡性淋巴瘤患者以及特定的晚期上皮样肉瘤患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","07226","00013","BK4007","BK4531","YANG","BK1191","HSTECH","BK4588","BK4585","BK1588","BK1587","HSCEI"],"gpt_icon":0},{"id":"2449323564","title":"和黄医药(00013)上涨5.14%，报28.65元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449323564","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449323564?lang=zh_cn&edition=full","pubTime":"2024-07-05 13:56","pubTimestamp":1720158988,"startTime":"0","endTime":"0","summary":"7月5日，和黄医药(00013)盘中上涨5.14%，截至13:56，报28.65元/股，成交4304.01万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2023年年报，和黄医药营业总收入59.35亿元、净利润7.14亿元。7月31日，和黄医药将披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/05135641392365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4531","HCM","BK4007","BK1588","BK4585","00013","BK1587","BK1191","BK4588"],"gpt_icon":0},{"id":"2448457394","title":"和黄医药(00013.HK)他泽司他新药上市申请已获国家药监局受理并予以优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2448457394","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448457394?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:19","pubTimestamp":1720052340,"startTime":"0","endTime":"0","summary":"和黄医药公布，他泽司他用于治疗复发或难治性滤泡性淋巴瘤成人患者的新药上市申请已获国家药监局受理并予以优先审评。他泽司他是由益普生旗下公司Epizyme开发的全球同类首创的EZH2甲基转移酶抑制剂，已获美国食品药监局加速批准用于治疗特定的复发/难治性滤泡性淋巴瘤患者以及特定的晚期上皮样肉瘤患者。和黄医药达成一项战略合作，负责在内地、香港、澳门和台湾进行他泽司他的研究、开发、生产以及商业化。沽空资料截至 2024-07-03 16:25。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220520173823854_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220520173823854_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361228/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1588","HCM","BK1587","BK1191","00013","BK4531","BK4585","BK4588","BK4007"],"gpt_icon":0},{"id":"2448452468","title":"和黄医药(00013)：他泽司他(tazemetostat)用于治疗复发或难治性滤泡性淋巴瘤的中国新药上市申请获受理并获纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2448452468","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448452468?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:06","pubTimestamp":1720051592,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，他泽司他用于治疗复发或难治性滤泡性淋巴瘤成人患者的新药上市申请已获中国国家药品监督管理局受理并予以优先审评。一项在中国开展的多中心、开放标签的II期桥接研究，以及Epizyme在中国以外地区开展的临床研究支持了此项中国新药上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00013","BK4531","BK1588","HCM","BK4588","BK4585","BK1587","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":0.0634},{"period":"3month","weight":0.1479},{"period":"6month","weight":0.3273},{"period":"1year","weight":0.5361},{"period":"ytd","weight":0.0458}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.04629},{"month":2,"riseRate":0.375,"avgChangeRate":-0.008286},{"month":3,"riseRate":0.375,"avgChangeRate":-0.005299},{"month":4,"riseRate":0.555556,"avgChangeRate":0.042359},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.070144},{"month":6,"riseRate":0.666667,"avgChangeRate":0.076759},{"month":7,"riseRate":0.555556,"avgChangeRate":0.035577},{"month":8,"riseRate":0.5,"avgChangeRate":0.035365},{"month":9,"riseRate":0.375,"avgChangeRate":-0.043105},{"month":10,"riseRate":0.625,"avgChangeRate":0.00878},{"month":11,"riseRate":0.875,"avgChangeRate":0.147113},{"month":12,"riseRate":0.625,"avgChangeRate":0.007065}],"exchange":"NASDAQ","name":"和黄医药","nameEN":"Hutchison China Meditech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,HCM,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}